Cite
MLA Citation
José Baselga et al.. “Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.” Lancet oncology, vol. 18, no. 7, n.d., pp. 904–916. http://access.bl.uk/ark:/81055/vdc_100046945356.0x00000e